These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 25356732)

  • 21. 5-HT
    Kwan C; Huot P
    Neurodegener Dis Manag; 2019 Oct; 9(5):251-253. PubMed ID: 31580227
    [No Abstract]   [Full Text] [Related]  

  • 22. Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner.
    Rammes G; Eisensamer B; Ferrari U; Shapa M; Gimpl G; Gilling K; Parsons C; Riering K; Hapfelmeier G; Bondy B; Zieglgänsberger W; Holsboer F; Rupprecht R
    Mol Psychiatry; 2004 Sep; 9(9):846-58, 818. PubMed ID: 15024394
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations of dopamine and serotonin transmission in schizophrenia.
    Remington G
    Prog Brain Res; 2008; 172():117-40. PubMed ID: 18772030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
    Marek GJ
    Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates.
    Pandey SC; Davis JM; Pandey GN
    J Psychiatry Neurosci; 1995 May; 20(3):215-25. PubMed ID: 7786883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Neuroleptics and serotonin].
    Hery F; Hamon M
    Encephale; 1993; 19(5):525-32. PubMed ID: 7905821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New pharmacological approaches to the treatment of schizophrenia].
    Uzbay IT
    Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studies on the neuroendocrine role of serotonin.
    Jørgensen HS
    Dan Med Bull; 2007 Nov; 54(4):266-88. PubMed ID: 18208678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.
    Alex KD; Pehek EA
    Pharmacol Ther; 2007 Feb; 113(2):296-320. PubMed ID: 17049611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
    Stahl SM; Shayegan DK
    J Clin Psychiatry; 2003; 64 Suppl 19():6-12. PubMed ID: 14728084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin and dopamine interactions in psychosis prevention.
    Richtand NM; McNamara RK
    Prog Brain Res; 2008; 172():141-53. PubMed ID: 18772031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality.
    Svensson TH
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1145-58. PubMed ID: 14642973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT
    Zajdel P; Grychowska K; Mogilski S; Kurczab R; Satała G; Bugno R; Kos T; Gołębiowska J; Malikowska-Racia N; Nikiforuk A; Chaumont-Dubel S; Bantreil X; Pawłowski M; Martinez J; Subra G; Lamaty F; Marin P; Bojarski AJ; Popik P
    J Med Chem; 2021 Sep; 64(18):13279-13298. PubMed ID: 34467765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of 5-HT₃ receptor antagonists on peripheral and central diseases.
    Fakhfouri G; Rahimian R; Ghia JE; Khan WI; Dehpour AR
    Drug Discov Today; 2012 Jul; 17(13-14):741-7. PubMed ID: 22390946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of varenicline on sensory gating and exploratory behavior with pretreatment with nicotinic or 5-HT3A receptor antagonists.
    Kucinski A; Wersinger S; Stachowiak EK; Becker C; Lippiello P; Bencherif M; Stachowiak MK
    Behav Pharmacol; 2015 Feb; 26(1-2):217-26. PubMed ID: 25485645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.
    Millan MJ
    J Pharmacol Exp Ther; 2000 Dec; 295(3):853-61. PubMed ID: 11082417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.
    Haleem DJ
    Behav Pharmacol; 2015 Feb; 26(1-2):45-58. PubMed ID: 25503261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hippocampal serotonin depletion facilitates the enhancement of prepulse inhibition by risperidone: possible role of 5-HT(2C) receptors in the dorsal hippocampus.
    Adams W; van den Buuse M
    Neuropharmacology; 2011 Sep; 61(3):458-67. PubMed ID: 21477601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.